Novel Peptide Therapeutic
Treatment-resistant cancers (Glioblastoma, Breast, Colon, Lung, Pancreatic)
Pre-clinicalActive
Key Facts
Indication
Treatment-resistant cancers (Glioblastoma, Breast, Colon, Lung, Pancreatic)
Phase
Pre-clinical
Status
Active
Company
About Acomhal Research
Acomhal Research is a private, preclinical-stage biotech founded in 2018 and headquartered in San Diego, CA, USA, with an additional operational address in Roanoke, VA. The company is developing a novel peptide therapeutic designed to target and disrupt chemo-resistant cancer cells and cancer stem cells, aiming to prevent relapse and metastasis as an adjunct to existing treatments. It has secured non-dilutive funding through multiple SBIR/STTR grants and was part of the Johnson & Johnson Innovation JLABS cohort, positioning it for early-stage validation and partnership opportunities.
View full company profile